Increased toll-like receptor (TLR) 2 and TLR4 expression in monocytes from patients with type 1 diabetes: Further evidence of a proinflammatory state

Journal of Clinical Endocrinology and Metabolism

Volumn 93, Issue 2, 2008, Pages 578-583

  Devaraj, Sridevi ^a   Dasu, Mohan R ^a   Rockwood, Jason ^a   Winter, William ^b   Griffen, Steven C ^a   Jialal, Ishwarlal ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 N CARBOXYMETHYLLYSINE; HEMOGLOBIN A1C; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE; INTERLEUKIN 1BETA; MESSENGER RNA; MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC PATIENT; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MONOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

EID: 39049157857     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2007-2185     Document Type: Article

References (28)

1. Libby P, Nathan DM, Abraham K, Brunzell JD, Fradkin JE, Haffner SM, Hsueh W, Rewers M, Roberts BT, Savage PJ, Skarlatos S, Wassef M, Rabadan-Diehl C, National Heart, Lung, and Blood Institute, National Institute of Diabetes and Digestive and Kidney Diseases Working Group on Cardiovascular Complications of Type 1 Diabetes Mellitus 2005 Report of the National Heart, Lung, and Blood Institute-National Institute of Diabetes and Digestive and Kidney Diseases Working Group on Cardiovascular Complications of Type 1 Diabetes Mellitus. Circulation 111:3489-3493
2. Schram MT, Chaturvedi N, Schalkwijk C, Giorgino F, Ebeling P, Fuller JH, Stehouwer CD, EURODIAB Prospective Complications Study 2003 Vascular risk factors and markers of endothelial function as determinants of inflammatory markers in type 1 diabetes: the EURODIAB Prospective Complications Study. Diabetes Care 26:2165-2173
3. Schram MT, Chaturvedi N, Schalkwijk CG, Fuller JH, Stehouwer CD, EURODIAB Prospective Complications Study Group 2005 Markers of inflammation are cross-sectionally associated with microvascular complications and cardiovascular disease in type 1 diabetes-the EURODIAB Prospective Complications Study. Diabetologia 48:370-378
4. Schalkwijk CG, Poland DC, van Dijk W, Kok A, Emeis JJ, Drager AM, Doni A, van Hinsbergh VW, Stehouwer CD 1999 Plasma concentration of C-reactive protein is increased in type I diabetic patients without clinical macroangiopathy and correlates with markers of endothelial dysfunction: evidence for chronic inflammation. Diabetologia 42:351-357
5. Devaraj S, Glaser N, Griffen S, Wang-Polagruto J, Miguelino E, Jialal I 2006 Increased monocytic activity and biomarkers of inflammation in patients with type 1 diabetes. Diabetes 55:774-779
6. Targher G, Bertolini L, Zoppini G, Zenari L, Falezza G 2005 Increased plasma markers of inflammation and endothelial dysfunction and their association with microvascular complications in type 1 diabetic patients without clinically manifest macroangiopathy. Diabet Med 22:999-1004
7. Devaraj S, Cheung AT, Jialal I, Griffen SC, Nguyen, Glaser NS, Aoki T 2007 Evidence of increased inflammation and microcirculatory abnormalities in patients with type 1 diabetes and their role in microvascular complications. Diabetes 56:2790-2796
8. Li H, Sun B 2007 Toll-like receptor 4 in atherosclerosis. J Cell Mol Med 11:88-95
9. Trinchieri G, Sher A 2007 Cooperation of toll-like receptor signals in innate immune defence. Nat Rev Immunol 7:179-190
10. Stoll LL, Denning GM, Weintraub NL 2006 Endotoxin, TLR4 signaling and vascular inflammation: potential therapeutic targets in cardiovascular disease. Curr Pharm Des 12:4229-4245
11. Uematsu S, Akira S 2006 Toll-like receptors and innate immunity. J Mol Med 84:712-725
12. Mullick AE, Tobias PS, Curtiss LK 2006 Toll-like receptors and atherosclerosis: key contributors in disease and health? Immunol Res 34:193-209
13. Takeda K, Akira S 2001 Roles of Toll-like receptors in innate immune responses. Genes Cells 6:733-742
14. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults 2001 Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486-2497
15. Michelsen KS, Wong MH, Shah PK, Zhang W, Yano J, Doherty TM, Akira S, Rajavashisth TB, Arditi M 2004 Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc Natl Acad Sci USA 101:10679-10684
16. Liu X, Ukai T, Yumoto H, Davey M, Goswami S, Gibson 3rd FC, Genco CA 2007 Toll-like receptor 2 plays a critical role in the progression of atherosclerosis that is independent of dietary lipids. Atherosclerosis Apr 25; [Epub ahead of print]
17. Mullick AE, Tobias PS, Curtiss LK 2005 Modulation of atherosclerosis in mice by Toll-like receptor 2. J Clin Invest 115:3149-3156
18. Bjorkbacka H, Kunjathoor VV, Moore KJ, Koehn S, Ordija CM, Lee MA, Means T, Halmen K, Luster AD, Golenbock DT, Freeman MW 2004 Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways. Nat Med 10:416-421
19. Song MJ, Kim KH, Yoon JM, Kim JB 2006 Activation of Toll-like receptor 4 is associated with insulin resistance in adipocytes. Biochem Biophys Res Commun 346:739-745
20. Mohammad MK, Morran M, Slotterbeck B, Leaman DW, Sun Y, Grafenstein H, Hong SC, McInerney MF 2006 Dysregulated Toll-like receptor expression and signaling in bone marrow-derived macrophages at the onset of diabetes in the non-obese diabetic mouse. Int Immunol 18:1101-1113
21. Devaraj S, Chan E, Jialal I 2006 Direct demonstration of an antiinflammatory effect of simvastatin in subjects with the metabolic syndrome. J Clin Endocrinol Metab 91:4489-4496
22. Park Y, Park S, Yoo E, Kim D, Shin H 2004 Association of the polymorphism for Toll-like receptor 2 with type 1 diabetes susceptibility. Ann NY Acad Sci 1037:170-174
23. Creely SJ, McTernan PG, Kusminski CM, Fisher M, Da Silva NF, Khanolkar M, Evans M, Harte AL, Kumar S 2007 Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. Am J Physiol Endocrinol Metab 292:E740-E747
24. Dasu MR, Devaraj S, Jialal I 2007 High glucose induces IL-1β expression in human monocytes: mechanistic insights. Am J Physiol Endocrinol Metab 293:E337-E346
25. Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS 2006 TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest 116:3015-3025
26. Sundell J, Ronnemaa T, Laine H, Raitakari OT, Luotolahti M, Nuutila P, Knuuti J 2004 High-sensitivity C-reactive protein and impaired coronary vasoreactivity in young men with uncomplicated type 1 diabetes. Diabetologia 47:1888-1894
27. Hayaishi-Okano R, Yamasaki Y, Katakami N, Ohtoshi K, Gorogawa S, Kuroda A, Matsuhisa M, Kosugi K, Nishikawa N, Kajimoto Y, Hori M 2002 Elevated C-reactive protein associates with early-stage carotid atherosclerosis in young subjects with type 1 diabetes. Diabetes Care 25:1432-1438
28. Colhoun HM, Schlakwijk C, Rubens MB, Stehouwer CD 2002 C-reactive protein in type 1 diabetes and its relationship to coronary artery calcification. Diabetes Care 25:1813-1817